Danaher Corporation $DHR is Generation Investment Management LLP's 10th Largest Position

Key Points

• Generation Investment Management LLP increased its stake in Danaher Corporation by 33.2%, now owning over 3.1 million shares valued at approximately $651.5 million.
• Institutional investors own 79.05% of Danaher's stock, indicating strong confidence in the company's performance.
• Danaher recently reported earnings per share of $1.80, exceeding estimates, with guidance for FY 2025 set between $7.700 and $7.800 EPS.

Generation Investment Management LLP boosted its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 33.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,178,124 shares of the conglomerate's stock after purchasing an additional 791,662 shares during the period. Danaher comprises about 3.9% of Generation Investment Management LLP's investment portfolio, making the stock its 10th biggest position. Generation Investment Management LLP owned approximately 0.44% of Danaher worth $651,515,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Nuveen LLC purchased a new position in shares of Danaher in the first quarter valued at about $833,941,000. GAMMA Investing LLC lifted its position in shares of Danaher by 24,958.2% in the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after acquiring an additional 1,863,381 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Danaher by 4,248.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock valued at $376,347,000 after acquiring an additional 1,601,800 shares in the last quarter. Invesco Ltd. lifted its position in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after acquiring an additional 1,450,703 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its position in shares of Danaher by 460.6% in the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock valued at $309,558,000 after acquiring an additional 1,107,998 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Trading Up 0.6%

Shares of NYSE:DHR traded up $1.29 during trading hours on Friday, hitting $200.32. 2,837,584 shares of the company's stock traded hands, compared to its average volume of 2,859,442. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The business has a fifty day moving average price of $201.93 and a 200-day moving average price of $199.41. The firm has a market capitalization of $143.44 billion, a P/E ratio of 42.62, a price-to-earnings-growth ratio of 2.78 and a beta of 0.75. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same quarter in the previous year, the business earned $1.72 earnings per share. The company's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on DHR. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research report on Tuesday. Wells Fargo & Company reduced their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 23rd. Robert W. Baird lifted their target price on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Deutsche Bank Aktiengesellschaft reduced their target price on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Barclays reaffirmed an "overweight" rating and issued a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $246.35.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.